Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Alnylam Pharmaceuticals Inc (ALNY)  
$436.38 9.41 (2.11%) as of 4:30 Fri 11/21


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 137,634,000
Market Cap: 60.06(B)
Last Volume: 1,298,049 Avg Vol: 776,821
52 Week Range: $224.32 - $491.22
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  529
Guru Rank Value     : 3.6
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 36
Total Buy Value $0 $0 $0 $10,363
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 2
Total Shares Sold 81,802 190,333 321,427 555,260
Total Sell Value $37,263,381 $78,350,538 $114,270,017 $164,490,446
Total People Sold 6 8 10 12
Total Sell Transactions 11 21 53 78
End Date 2025-08-24 2025-05-23 2024-11-22 2023-11-23

   
Records found: 521
  Page 1 of 21  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-11-17 4 AS $449.00 $5,483,990 D/D (12,128) 21,264 -5%     
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-11-17 4 OE $119.13 $972,220 D/D 8,161 33,392     -
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-11-13 4 AS $447.73 $4,512,682 D/D (10,000) 65,409 -4%     
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-11-13 4 OE $119.13 $1,191,300 D/D 10,000 75,409     -
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-11-12 4 AS $448.07 $7,100,322 D/D (15,650) 65,409 -4%     
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-11-12 4 OE $42.22 $1,814,393 D/D 15,650 81,059     -
   Garg Pushkal EVP Chief R&D   •       –      –    2025-10-03 4 AS $449.99 $1,364,387 D/D (3,022) 20,221 -4%     
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-10-02 4 S $446.53 $1,103,451 D/D (2,441) 25,231 3%     
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2025-10-02 4 S $446.53 $1,727,284 D/D (3,821) 54,052 3%     
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-10-02 4 S $446.53 $4,034,085 D/D (8,924) 65,409 3%     
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2025-10-02 4 S $446.53 $635,126 D/D (1,405) 27,438 3%     
   Garg Pushkal EVP Chief R&D   •       –      –    2025-10-02 4 AS $446.53 $1,327,675 D/D (2,937) 23,243 -5%     
   Fitzgerald Kevin Joseph CSO & EVP, Head of Research   •       –      –    2025-10-01 4 A $0.00 $0 D/D 4,953 27,672     -
   Supran Bryan EVP, CLO and Secretary   •       –      –    2025-10-01 4 A $0.00 $0 D/D 13,026 13,026     -
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2025-10-01 4 A $0.00 $0 D/D 7,752 57,873     -
   Greenstreet Yvonne Chief Executive Officer   •       •      –    2025-10-01 4 A $0.00 $0 D/D 18,112 74,333     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2025-10-01 4 A $0.00 $0 D/D 2,851 28,843     -
   Garg Pushkal EVP Chief R&D   •       –      –    2025-10-01 4 A $0.00 $0 D/D 5,959 26,180     -
   Reitan Colleen F Director   –       •      –    2025-09-09 4 AS $457.44 $8,416,730 D/D (18,000) 775 -9%     
   Reitan Colleen F Director   –       •      –    2025-09-09 4 OE $100.65 $1,811,700 D/D 18,000 18,775     -
   Tanguler Tolga EVP, Chief Commercial Officer   •       –      –    2025-08-29 4 AS $445.53 $1,557,649 D/D (3,474) 25,992 -2%     
   Garg Pushkal EVP Chief R&D   •       –      –    2025-08-19 4 AS $455.41 $666,987 D/D (1,455) 20,221 -5%     
   Bonney Michael W Director   –       •      –    2025-08-18 4 AS $450.00 $5,062,500 D/D (11,250) 16,804 -4%     
   Bonney Michael W Director   –       •      –    2025-08-18 4 OE $70.20 $789,750 D/D 11,250 28,054     -
   Poulton Jeffrey V. EVP, Chief Financial Officer   •       –      –    2025-08-18 4 S $447.98 $1,030,727 D/D (2,274) 50,121 2%     
  521 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 21
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us